Hazardous Drugs

A public meeting was held on August 28, 2007, in Washington, DC, to discuss and obtain comments on the draft document, “NIOSH Hazardous Drugs List Update.”

Pre-meeting Information

Notice of request for public to submit comments and attend public meeting; 72 FR 33507; 6/18/07 [PDF - 1,290 KB]

List of new FDA drugs and warnings fitting NIOSH criteria for hazardous drugs; 2006 [PDF - 2,480 KB]

NIOSH Alert, “Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings,” DHHS (NIOSH) Publication No. 2004-105 [PDF - 15,910 KB]

List of new FDA drugs and warnings not fitting NIOSH criteria for hazardous drugs, 2006 [PDF - 3,670 KB]

Meeting Information

Presentation by Reed/Connor (NIOSH) at the NIOSH Public Meeting on Hazardous Drugs List Update; Washington, DC; 8/28/07 [PDF - 2,620 KB]

List of attendees – 8/27/07 [PDF - 44 KB]

Post-Meeting Information

Transcript of the NIOSH Public Meeting on Hazardous Drugs List Update; Washington, DC; 8/28/07; Part 1 [PDF - 22,780 KB]

Transcript of the NIOSH Public Meeting on Hazardous Drugs List Update; Washington, DC; 8/28/07; Part 2 [PDF - 20,830 KB]

Submission to the docket from private person – 6/14/07 [PDF - 279 KB]

Submission to the docket from private person – 6/19/07 [PDF - 17 KB]

Submission to the docket from private person – 6/19/07 [PDF - 23 KB]

Submission to the docket from private person – 6/19/07 [PDF - 295 KB]

Submission to the docket from Thies (St. Luke’s Hospital) – 6/22/07 [PDF - 205 KB]

Submission to the docket from Olson (GlaxoSmithKline) – 8/1/07 [PDF - 196 KB]

Submission to the docket from Fabbro (BC Cancer Agency) – 8/24/07 [PDF - 535 KB]

Submission to the docket from Werner (The National Home Infusion Association) – 8/27/07 [PDF - 675 KB]

Submission to the docket from Schmidt (Western Missouri Mental Health Center) – 8/28/07 [PDF - 1,490 KB]

Submission to the docket from private person – 9/6/07 [PDF - 4,360 KB]

Submission to the docket from private person – 9/8/07 [PDF - 177 KB]

Submission to the docket from Swyres (Barnes-Jewish Hospital) – 9/10/07 [PDF - 2,690 KB]

Submission to the docket from private person – 9/11/07 [PDF - 151 KB]

Submission to the docket from private person – 9/12/07 [PDF - 20 KB]

Submission to the docket from Suter (Novartis Pharma AG) – 9/17/07 [PDF - 984 KB]

Submission to the docket from Wylie (Wyeth) – 9/18/07 [PDF - 1,580 KB]

Submission to the docket from Murano (Genentech, Inc) – 9/18/07 [PDF - 9,420 KB]

Submission to the docket from Oliver (AstraZeneca) – 9/19/07 [PDF - 5,090 KB]

Submission to the docket from Hung (Mayo Clinic) – 9/19/07 [PDF - 12,620 KB]

Submission to the docket from Reilly/Coffey (American Society of Health-System Pharmacists) – 9/20/07 [PDF - 4,760 KB]

Submission to the docket from Collura (Clarian Health) – 9/20/07 [PDF - 1,690 KB]

Submission to the docket from Roman (Boehringer Ingelheim Pharmaceuticals, Inc) – 9/20/07 [PDF - 6,420 KB]

Submission to the docket from Roman (Ben Venue Laboratories) – 9/20/07 [PDF - 216 KB]

Submission to the docket from Schwartz (Pfizer Inc) – 9/20/07 [PDF - 3,090 KB]

Submission to the docket from Sigler (Kaiser Permanente) – 9/20/07 [PDF - 153 KB]

Submission to the docket from Treanor (BioPharma EHS Forum) – 9/20/07 [PDF - 2,730 KB]

Submission to the docket from White (Pharmaceutical Research and Manufacturers of America) – 9/20/07 [PDF - 4,730 KB]

Submission to the docket from Bough/Gans (American Pharmacists Association) – 9/20/07 [PDF - 2,870 KB]

Submission to the docket from Stewart (Kaiser Permanente) – 9/21/07 [PDF - 186 KB]

Submission to the docket from Cadsap (Tercica) – 9/26/07 [PDF - 2,100 KB]

Submission to the docket from McHugh (Gilead Sciences, Inc) – 9/26/07 [PDF - 29,120 KB]

Submission to the docket from Olson (GlaxoSmithKline) – 9/20/07 [PDF - 2,340 KB]

Submission to the docket from McGrath (Bristol-Myers Squibb Company) – 9/28/07 [PDF - 4,830 KB]

Submission to the docket from Olson (GlaxoSmithKline) – 12/12/07 [PDF - 420 KB]

Submission to the docket from Cormack (Sucampo Pharmaceuticals) – 1/22/08 [PDF - 1,960 KB]